France-based Sanofi has confirmed this week a significant €350m (CA$500m) investment to build a vaccine production plant in its plant in Toronto, Canada. The new investment makes the Canadian site one of the main plants of the group, with over 1,400 employees. The project, due to be completed before 2021, will benefit from a €32m incentive from the Province of Ontario and a €13m one from the Government of Canada.
The new plant will produce antigens, to be used to create vaccines for conditions such as diphtheria and tetanus. Sanofi last year announced another significant €170m investment on a new plant in Val de Reuil (Normandy), to be used to produce flu vaccines.
(Source: Les Echos)